2024 ESC高血压指南应用于挪威40岁普通人群队列:Akershus心脏检查1950研究
该研究将2024 ESC高血压指南应用于挪威1950年出生队列,评估40岁和62-65岁时因血压升高(eBP,130-139/80-89 mm Hg)且心血管风险升高而符合药物治疗资格的比例,并追踪30年主要不良心血管事件(MACE)。结果显示40岁时eBP常见但符合药物治疗者极少,eBP人群中的MACE主要发生在不符合药物治疗者中。
要点
- 40岁时32%个体有eBP(130-139/80-89 mm Hg),仅4人因心血管风险升高符合药物治疗。
- 62-65岁时eBP者中8%符合药物治疗,61%已用药或血压≥140/90。
- eBP人群中MACE主要发生于不符合药物治疗者。
核心结论
- 40岁时单次血压测量识别出eBP者占三分之一,但eBP人群中的MACE主要发生在不符合药物治疗的个体中。
研究设计与样本
- 研究基于1950年出生并参与40岁计划及Akershus心脏检查1950研究的个体,链接国家健康登记数据,包括40岁(1990-1991)和62-65岁(2012-2015)血压测量、基于SCORE2的心血管风险升高评估及至2022年的MACE结局。
主要发现
- 40岁时2688人中854人(32%)有eBP(130-139/80-89 mm Hg),仅4人有心血管风险升高需药物治疗。
- 62-65岁时1657人(61%)使用降压药或血压≥140/90,851名eBP者中64人(8%)符合药物治疗。
- 基于40岁血压值,eBP(130-139/80-89 mm Hg)类别93例MACE中仅2例发生于符合药物治疗者。
关键数值与推荐
- 2024 ESC指南引入eBP类别(120-139/70-89 mm Hg),持续性eBP(130-139/80-89 mm Hg)且心血管风险升高者可在生活方式干预后考虑药物治疗。
临床怎么用
- 40岁时eBP常见但符合药物治疗者极少,eBP人群的MACE主要发生在不符合药物治疗者中,提示需关注该人群的长期风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2024 European Society of Cardiology (ESC) Guidelines for hypertension introduced the 'elevated BP' (eBP) category (120-139/70-89 mm Hg). Individuals with persistent eBP (130-139/80-89 mm Hg), despite lifestyle intervention, may be recommended pharmacological treatment in case of concomitant elevated cardiovascular (CV) risk. We aimed to assess the impact of these updated recommendations on treatment eligibility at ages 40 and 62-65 and to examine the CV event rates over 30 years of follow-up, focusing on those with eBP (130-139/80-89 mm Hg) eligible for pharmacological treatment. METHODS: Data from individuals born in 1950 who participated in the Age 40 Programme and the Akershus Cardiac Examination 1950 Study was linked to national health registries. These data include BP measurements at age 40 (1990-1991) and 62-65 (2012-2015), assessment of elevated CV risk based on Systematic Coronary Risk Evaluation 2 (SCORE2) and outcomes of major adverse cardiovascular events (MACEs) tracked through 2022. RESULTS: At age 40, 854 (32%) of 2688 individuals had eBP (130-139/80-89 mm Hg), but only 4 had elevated CV risk warranting pharmacological treatment. At age 62-65, 1657 (61%) were on BP-lowering medication or had a BP ≥140/90, while 64 (8%) out of 851 with eBP were eligible for drug treatment. Based on BP values at age 40, only 2 of the 93 MACEs in the eBP (130-139/80-89 mm Hg) category occurred among those eligible for pharmacological treatment. CONCLUSIONS: A single BP measurement at age 40 identified eBP (130-139/80-89 mm Hg) among one-third of the individuals, yet MACE cases within the eBP category occurred primarily in individuals who were not eligible for medical treatment.
引用
- Ihle-Hansen H, Walle-Hansen MM, Hagberg G, et al. Applying the 2024 European Society of Cardiology Guidelines for the management of elevated blood pressure and hypertension to a Norwegian general population cohort from age 40: data from the Akershus Cardiac Examination 1950 study. Heart. 2025. PMID: 40404281. doi:10.1136/heartjnl-2025-325770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。